Quick Answer
CNS Pharmaceuticals, Inc. reported Research And Development Expense of $9.77 million for the year ending 2025.
- CNS Pharmaceuticals, Inc. showed an increase of +5.2% in Research And Development Expense from 2024 to 2025.
- This data is from CNS Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: $4.6 thousand | Q1 2019: $48.3 thousand | Q2 2019: $42.7 thousand | Q3 2019: $325.6 thousand | Q1 2020: $613.1 thousand | Q2 2020: $1.49 million | Q3 2020: $1.04 million | Q1 2021: $2.21 million | Q2 2021: $2.66 million | Q3 2021: $2.58 million | Q1 2022: $1.89 million | Q2 2022: $2.22 million | Q3 2022: $2.21 million | Q1 2023: $3.57 million | Q2 2023: $2.85 million | Q3 2023: $3.41 million | Q1 2024: $2.43 million | Q2 2024: $1.12 million | Q3 2024: $4.24 million | Q1 2025: $3.24 million | Q2 2025: $1.17 million | Q3 2025: $2.20 million.
- Over the full 8 years of available data (2018 to 2025), CNS Pharmaceuticals, Inc.'s Research And Development Expense has grown by 45,848.8%.
- Historical annual values: Fiscal year 2025: $9.77 million | Fiscal year 2024: $9.29 million | Fiscal year 2023: $14.10 million | Fiscal year 2022: $9.30 million | Fiscal year 2021: $9.81 million | Fiscal year 2020: $5.06 million | Fiscal year 2019: $1.85 million | Fiscal year 2018: $21.3 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: